CONTROLLED RELEASE PARENTERAL DELIVERY SYSTEM

国家药物滥用研究所(NIDA)的一项主要计划是 开发治疗药物成瘾的新药物疗法。 维持有效药物的控释制剂 集中很长一段时间，从而减轻需要 对于频繁的药物管理提供了比传统药物更多的优势 剂型。这类准备工作尤其适用于 治疗药物成瘾，因为长期治疗通常是 要求和患者的遵从性可能是一个问题。此外, 治疗毒品成瘾的缓释制剂 有助于最大限度地利用现有的治疗资源，这是一个问题 鉴于对……的作用的关切，日益重要 艾滋病流行中的静脉注射吸毒者。 本合同的目的是开发一种临床上有用的可控- 释放制剂为缓释片提供丁丙诺啡效果 一段时间。丁丙诺啡是一种部分阿片激动剂，已被 被证明对治疗阿片类药物依赖有效。在.期间 合同的第一阶段，几个不同的微球 丁丙诺啡制剂已被制备和表征。 丁丙诺啡控释制剂的可行性研究 系统已经过演示。在第二阶段期间， 承包商将继续开发一套父母交付系统 丁丙诺啡适合临床使用。

A major program of the National Institute on Drug Abuse (NIDA) is to develop new pharmacotherapeutics for the treatment of drug addiction. Controlled-release preparations which maintain an effective drug concentration for a long period of time and therefore alleviate the need for frequent drug administration offer advantages over conventional dosage forms. Such preparations are particularly useful in the treatment of drug addiction, because long-term treatment is usually required and patient compliance can be a problem. In addition, sustained-release preparations for the treatment of narcotic addiction could help maximize the existing treatment resources, an issue of increasing importance in view of the concern over the role of intravenous drug abusers in the AIDS epidemic. The purpose of this contract is to develop a clinically useful controlled- release preparation to provide buprenorphine effects for an extended period of time. Buprenorphine is a partial opioid agonist and has been shown to be effective for the treatment of opioid dependence. During the phase I period of the contract, several different microsphere formulations of buprenorphine have been prepared and characterized. The feasibility of developing a controlled-release buprenorphine delivery system has been demonstrated. During the phase II period, the contractor will continue to develop a parental delivery system of buprenorphine suitable for clinical use.